Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells.
Zhu GQ, Tang Z, Chu TH, Wang B, Chen SP, Tao CY, Cai JL, Yang R, Qu WF, Wang Y, Zhao QF, Huang R, Tian MX, Fang Y, Gao J, Wu XL, Zhou J, Liu WR, Dai Z, Shi YH, Fan J.
Zhu GQ, et al. Among authors: cai jl.
Signal Transduct Target Ther. 2025 Jan 22;10(1):25. doi: 10.1038/s41392-024-02118-2.
Signal Transduct Target Ther. 2025.
PMID: 39837814